Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.
Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.
The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.
Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.
Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.
Zoetis reported a strong financial performance for Q3 2021, with revenue of $2.0 billion, an 11% increase year-over-year, and net income of $552 million, up 15%. Adjusted net income rose to $597 million, or $1.25 per diluted share, marking a 14% increase. The company is optimistic, raising its full-year revenue guidance to $7.700 - $7.750 billion and diluted EPS to $4.23 - $4.29. Key growth drivers included strong sales in petcare products and new monoclonal antibodies, despite facing challenges in livestock product sales.
Zoetis Inc. (NYSE:ZTS) announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development effective January 1, 2022. He succeeds Dr. Catherine Knupp, who plans to retire after leading Zoetis' R&D efforts since the company's inception in 2013. Under her guidance, Zoetis launched over 1,100 new products in five years and established a strong portfolio in animal health. Polzer, previously Senior VP of Global Therapeutics, brings over 20 years of R&D experience and aims to drive continuous innovation in Zoetis' diverse product pipeline.
Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2021 dividend of $0.25 per share, payable on December 1, 2021, to stockholders on record as of October 29, 2021. As a leader in animal health, Zoetis generated revenue of $6.7 billion in 2020, supported by a workforce of approximately 11,300 employees. The company focuses on advancing animal care through innovations in medicines, vaccines, and diagnostics globally.
Zoetis Inc (NYSE:ZTS) will host a webcast on November 4, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and address questions from analysts. Interested parties can access the live webcast on the Zoetis investor relations website. A replay will be available after the event. Zoetis generated $6.7 billion in revenue in 2020 and has a strong portfolio of animal health products.
Zoetis has been recognized for the eighth consecutive year as one of Seramount’s 100 Best Companies, underscoring its commitment to family-friendly benefits and flexible work arrangements. Notably, Kristy Earley-Murray was named Working Mother of the Year, and Chip Dorsey is the first recipient of Working Father of the Year. These honors highlight Zoetis' dedication to supporting working parents, particularly during the ongoing challenges posed by the COVID-19 pandemic, as stated by Executive VP Roxanne Lagano.
Zoetis (NYSE:ZTS) will participate in the Jefferies Virtual Pet Care Summit on September 16, 2021. Executive Vice President Glenn David will represent the company during the presentation at 11:00 a.m. ET. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations. A replay will be available afterward. Zoetis, a leader in animal health, generated $6.7 billion in revenue in 2020, employs approximately 11,300 individuals, and operates in over 100 countries.
Zoetis reported a strong Q2 2021, with revenue of $1.9 billion, a 26% increase year-over-year, and net income up 36% to $512 million. Adjusted net income rose 33% to $566 million ($1.19 per share). U.S. revenue grew 22%, driven by a 34% rise in companion animal products, while international sales surged 31%. The company raised its full-year guidance, projecting revenue between $7.625 billion and $7.700 billion, reflecting strong growth drivers despite expectations of modest growth in H2 2021.
Zoetis (NYSE: ZTS) announced an agreement to acquire Jurox, an animal health company known for its veterinary medicines for companion animals and livestock. This acquisition will enhance Zoetis' global expansion efforts, particularly in Australia, its fifth-largest market with $207 million in revenue in 2020. Jurox brings a valuable product portfolio, including Alfaxan®, and over 150 products aimed at animal health. The transaction, awaiting regulatory approval, is expected to close in the first half of 2022.
Zoetis is donating over 11,000 doses of its experimental COVID-19 vaccine to protect more than 100 mammalian species in nearly 70 zoos across 27 states. Authorized for use by the USDA, the vaccine aims to combat COVID-19 risks in at-risk animals, such as tigers and gorillas. The first vaccinations began at Oakland Zoo on June 30, 2021. The vaccine utilizes a unique formulation for animals, developed from Zoetis' extensive experience with other coronaviruses. This initiative reflects Zoetis' commitment to animal health and sustainability, as they monitor emerging infectious diseases.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Aug. 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live webcast on the Zoetis investor site. The company, a leader in animal health, achieved $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on medicines, vaccines, and services for animal care.
FAQ
What is the current stock price of ZOETIS (ZTS)?
What is the market cap of ZOETIS (ZTS)?
What does Zoetis Inc. specialize in?
Is Zoetis Inc. still part of Pfizer?
What percentage of Zoetis' revenue comes from companion animals?
Which segment contributes more to Zoetis' U.S. business?
How does Zoetis' international business differ from its U.S. business?
What recent achievements has Zoetis Inc. accomplished?
What are Zoetis' current projects?
What is Zoetis' market position in the industry?
Does Zoetis have any strategic partnerships?
Where can I find the latest updates on Zoetis Inc.?
